TY - JOUR
T1 - Comparison of six pharmacologic regimens for hypercholesterolemia
AU - Hoeg, Jeffrey M.
AU - Maher, Martha B.
AU - Bailey, Kent R.
AU - Brewer, H. Bryan
N1 - Funding Information:
From the Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. Manuscript received October 22,1986; revised manuscript received November 6.1986, accepted November 7,1986.
PY - 1987/4/1
Y1 - 1987/4/1
N2 - Six sequential clinical trials were conducted over 5 years to evaluate the safety and efficacy of different treatment regimens for hypercholesterolemia. Of all the study participants, 11 patients were evaluated in all 6 clinical trials using the following regimens: neomycin, neomycin/niacin, cholestyramine, cholestyramine/neomycin, lovastatin and lovastatin/neomycin. All 6 regimens significantly (p <0.05) reduced both total and low-density lipoprotein cholesterol concentrations by 25 to 42 % from baseline levels. Only neomycin/niacin, cholestyramine and lovastatin significantly increased the high-density lipoprotein (HDL) cholesterol concentration, reducing the total cholesterol/high-density lipoprotein cholesterol ratio to less than 4.7. Thus, all 6 tested regimens were effective in modifying the plasma lipoprotein concentrations in type 11 hyperlipoproteinemia, but neomydn/niacin, cholestyramine and lovastatin had the most favorable Impact. Only lovastatin treatment was free of adverse effects.
AB - Six sequential clinical trials were conducted over 5 years to evaluate the safety and efficacy of different treatment regimens for hypercholesterolemia. Of all the study participants, 11 patients were evaluated in all 6 clinical trials using the following regimens: neomycin, neomycin/niacin, cholestyramine, cholestyramine/neomycin, lovastatin and lovastatin/neomycin. All 6 regimens significantly (p <0.05) reduced both total and low-density lipoprotein cholesterol concentrations by 25 to 42 % from baseline levels. Only neomycin/niacin, cholestyramine and lovastatin significantly increased the high-density lipoprotein (HDL) cholesterol concentration, reducing the total cholesterol/high-density lipoprotein cholesterol ratio to less than 4.7. Thus, all 6 tested regimens were effective in modifying the plasma lipoprotein concentrations in type 11 hyperlipoproteinemia, but neomydn/niacin, cholestyramine and lovastatin had the most favorable Impact. Only lovastatin treatment was free of adverse effects.
UR - http://www.scopus.com/inward/record.url?scp=0023187504&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023187504&partnerID=8YFLogxK
U2 - 10.1016/0002-9149(87)91097-6
DO - 10.1016/0002-9149(87)91097-6
M3 - Article
C2 - 3644588
AN - SCOPUS:0023187504
SN - 0002-9149
VL - 59
SP - 812-815,816
JO - The American journal of cardiology
JF - The American journal of cardiology
IS - 8
ER -